RLMD Insider Trading Activity and SEC Form 4 Filings
RLMD insider trading summary
Over the past 12 months, insiders at Relmada Therapeutics, Inc. (RLMD) reported 6 open-market purchases worth $1.8M by 2 insiders and no sales on SEC Form 4. Net insider buying was $1.8M.
Latest RLMD insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 10, 2026 | Maged Shenouda | Chief Financial Officer | Buy | $339K (79,800 @ $4.25) |
| Sep 10, 2026 | Sergio Traversa | Chief Executive Officer | Buy | $410K (100,000 @ $4.10) |
| Sep 9, 2026 | Maged Shenouda | Chief Financial Officer | Buy | $505K (120,200 @ $4.20) |
| Sep 9, 2026 | Sergio Traversa | Chief Executive Officer | Buy | $418K (100,000 @ $4.18) |
| Dec 15, 2025 | Sergio Traversa | Chief Executive Officer | Buy | $113K (27,500 @ $4.12) |
| Dec 15, 2025 | Maged Shenouda | Chief Financial Officer | Buy | $48K (11,665 @ $4.12) |
| Nov 5, 2025 | Chuck Ence | CAO and COO | Buy | $299K (136,000 @ $2.20) |
| Nov 5, 2025 | Maged Shenouda | Chief Financial Officer | Buy | $1.1M (500,000 @ $2.20) |
| Nov 5, 2025 | Paul Edward Kelly | Chief Operating Officer | Buy | $198K (90,000 @ $2.20) |
| Nov 5, 2025 | Sergio Traversa | Chief Executive Officer | Buy | $600K (272,500 @ $2.20) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.